Pharmaceutical and life sciences

Helping clients better compete in an evolving health market and improve cost-efficiency and profitability

Top health industry issues of 2019: The New Health Economy comes of age

The US health industry has often lagged other industries when it comes to modernizing. Once thought to operate outside the greater US economy, the industry—with its byzantine payment system, complicated regulatory barriers and reliance on face-to-face interactions—is being disrupted. Finally, there’s robust evidence that what PwC calls the New Health Economy is kicking into gear.

Learn more

The potential impact of tax reform on pharmaceutical and life sciences companies 

From President Trump's tax plan to healthcare reform—we break down developments from Washington and what companies in our industry need to do to anticipate and prepare for legislative change.

Learn more

{{filterContent.facetedTitle}}

Contact us

Karen C. Young

US Pharmaceutical and Life Sciences Leader, PwC US

Tel: +1 (973) 236 5648

Michael Swanick

Global Pharmaceutical and Life Sciences Leader, PwC US

Tel: +1 (267) 330 6060

Kathleen Michael

US Health Industries Tax Leader, PwC US

Tel: +1 (973) 236 4210

Douglas Strang

Global Pharmaceutical and Life Sciences Advisory Leader, PwC US

Tel: +1 (267) 330 3045

Rick Edmunds

Principal, Strategy&, PwC US

Tel: +1 (703) 682 5755

Glenn Hunzinger

US Pharmaceutical and Life Sciences Deals Leader, PwC US

Tel: +1 (646) 818 7742

Laura Robinette

US Pharmaceutical & Life Sciences Assurance Leader, PwC US

Tel: +1 (919) 791 4100

Craig Cleaver

US Pharmaceutical and Life Sciences Risk Assurance Leader, PwC US

Tel: +1 (267) 330 2908

Follow us